Aoife most recently served as Synlogic’s president and CEO. Aoife is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Prior to Synlogic, Aoife served as head of the Rare Disease Innovation Unit at Biogen developing programs from pre-clinical to commercial across multiple therapeutic areas including successful late phase development & registration of SPINRAZA® (nusinersen) for spinal muscular atrophy and ALPROLIX® and ELOCTATE® for Hemophilia B and Hemophilia A. Aoife serves on the Board of Directors of Cerevance and Fibrogen, Inc. She holds a medical degree from Trinity College and completed post-doctoral training in clinical research and metabolism at Beth Israel Deaconess Medical Center.